Brandon BioCatalyst’s investors include Australia’s leading superannuation funds and Australia’s largest biotechnology company, CSL.
By investing in biotech discoveries, our superannuation funds are generating long-term, superior returns on behalf of their superannuate investors, as well as creating local jobs and contributing to the growth of a sunrise industry. This is a virtuous circle where jobs are created and returns are generated for our aging population. At the same time, outcomes from this investment support an ageing population, lower the cost of healthcare and ultimately, improve patient outcomes.
Australia and New Zealand are two of the world’s leaders in biomedical research and drug discovery. Pharmaceutical and medical products represent Australia’s largest export industry, in terms of manufactured products, with huge potential for growth and expansion in the future.
By supporting Brandon BioCatalyst, investors are seeking out superior returns for their members from a growing sector at the forefront of innovation.
As well as offering strong financial returns, their investment supports job creation, economic growth and improved health outcomes for all.
